Goelzer Investment Management Inc. Sells 5,886 Shares of Eli Lilly and Company (NYSE:LLY)

Goelzer Investment Management Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 1.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 583,401 shares of the company’s stock after selling 5,886 shares during the quarter. Eli Lilly and Company comprises approximately 25.7% of Goelzer Investment Management Inc.’s holdings, making the stock its largest position. Goelzer Investment Management Inc. owned approximately 0.06% of Eli Lilly and Company worth $453,863,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Lipe & Dalton bought a new stake in Eli Lilly and Company during the fourth quarter worth approximately $26,000. Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth $29,000. Core Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the period. Frank Rimerman Advisors LLC bought a new position in Eli Lilly and Company during the fourth quarter valued at about $37,000. Finally, St. Johns Investment Management Company LLC grew its holdings in Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after acquiring an additional 37 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.5 %

Shares of NYSE:LLY traded up $5.03 during mid-day trading on Monday, reaching $919.60. The stock had a trading volume of 916,642 shares, compared to its average volume of 2,931,884. The firm has a market cap of $873.99 billion, a PE ratio of 136.20, a price-to-earnings-growth ratio of 1.99 and a beta of 0.41. The firm has a 50 day simple moving average of $831.69 and a two-hundred day simple moving average of $752.53. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $928.60.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the company posted $1.62 earnings per share. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the sale, the insider now owns 97,299,772 shares in the company, valued at $89,059,454,309.32. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 858,742 shares of company stock worth $735,573,781 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on LLY shares. Truist Financial reissued a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Argus raised their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Bank of America reaffirmed a “buy” rating and issued a $1,000.00 price target on shares of Eli Lilly and Company in a report on Monday, June 24th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $1,001.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, July 3rd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $816.78.

Read Our Latest Stock Analysis on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.